Yvette Zimmerman new CEO Pantarhei Bioscience: “We find safe and effective new treatments using existing human molecules.”

Pantarhei Bioscience, the Dutch biopharmaceutical company, is pleased to announce the appointment of Yvette Zimmerman as Chief Executive Officer (CEO), with effect from January 2019. The founder of Pantarhei Herjan Coelingh Bennink speaks proudly about his successor: “Yvette is a very experienced drug developer and driven by what is really important for people and scientifically sound.”

During the 18 years of its existence, Pantarhei has filed more than 220 patents. Initially Pantarhei developed new medicines for Women’s Health. Following the foundation of the subsidiary company Pantarhei Oncology in 2014, the focus has been redirected to new treatment concepts for endocrine cancer, especially breast and prostate cancer.

Read more: Press Release New CEO Pantarhei Bioscience

Yvette Zimmerman nieuwe CEO Pantarhei Bioscience: “Wij ontdekken veilige en effectieve nieuwe geneesmiddelen op basis van bestaande menselijke moleculen.”

Het Nederlandse biofarmaceutische bedrijf Pantarhei Bioscience heeft met ingang van januari 2019 haar Chief Operating Officer (COO) Yvette Zimmerman benoemd tot Chief Executive Officer (CEO). De oprichter en voormalig CEO van Pantarhei, Herjan Coelingh Bennink, is trots op zijn opvolgster: “Yvette is een zeer ervaren ontwikkelaar van nieuwe geneesmiddelen, gemotiveerd door wat echt belangrijk is voor zieke mensen en wat wetenschappelijk vernieuwend is.”

Pantarhei bestaat nu 18 jaar en heeft in die tijd meer dan 220 patenten ingediend. Oorspronkelijk was Pantarhei gericht op het ontwikkelen van nieuwe geneesmiddelen op het gebied van Women’s Health. Sinds de oprichting van het dochterbedrijf Pantarhei Oncology in 2014, is de focus verlegd naar nieuwe hormonale behandelingen van kanker, met name borst- en prostaatkanker.

Lees verder: Persbericht Nieuwe CEO Pantarhei Bioscience

Zwangerschapshormoon Estetrol effectief bij behandeling van borstkanker

Pantarhei Oncology rapporteert positieve resultaten van de behandeling van borstkanker met het zwangerschapshormoon Estetrol.

Persbericht Pantarhei Oncology 6 december 2018

Fetal estrogen Estetrol effective for breast cancer treatment

Pantarhei Oncology announces favorable efficacy results of the fetal estrogen Estetrol in women with advanced breast cancer.

Press release Pantarhei Oncology December 6 2018

16th World congress on Menopause, June 6-9, 2018, Vancouver, Canada

On Friday June 8, 2018, the CSO of Pantarhei Carole Verhoeven lectured on the treatment of breast cancer with the fetal estrogen estetrol in a scientific symposium entitled ‘Estrogens and breast cancer’. The other lecture (A lesson in contracts. What can we learn from the discrepant breast cancer findings in the WHI?) was presented by Bob Langer. The symposium was chaired by Wulf Utian.

For more information, please read the abstract: Abstract IMS Treatment of breast cancer with the fetal estrogen estetrol.

 

 

First patient randomized in the PCombi study with Estetrol in patients with prostate cancer.

On 3 May 2018 the first patient has been randomized in the phase IIA clinical study assessing efficacy and safety of the fetal estrogen estetrol (E4) in prostate cancer patients. The study is a double blind, randomised, placebo-controlled multi-center study in prostate cancer patients treated with an LHRH agonist. In total 60 patients will be enrolled at eight centers in the Netherlands.

The main objectives of this study are to evaluate the additional effect of E4 on testosterone (T) suppression (total T as well as free T) by the LHRH agonist as well as the prevention and treatment of hypoestrogenic side effects due to the concomitant suppression of estrogens.

 

 

ISGE, March 7-10, 2018, Florence, Italy

On March 8, 2018 Pantarhei Bioscience participated in a scientific symposium entitled Estetrol and Breast Cancer. The lectures were presented by Richard J. Santen (Estetrol in animal in vivo studies), Risto Erkkola (Estetrol in ex vivo explant cultures of human breast cancer tissue) and Herjan Coelingh Bennink (Estetrol treatment of advanced breast cancer). The symposium was chaired by Ludwig Kiesel and Herjan Coelingh Bennink.

 

25th World Congress on Controversies in Obstetrics, Gynecology & Infertility (COGI) November 30- December 2, 2017, Vienna, Austria

On Friday December 1, 2017, the CEO of Pantarhei Herjan Coelingh Bennink lectured during the session: Breast cancer risk from hormonal treatment.

The title of the lecture qualified by the organisers as countercurrent was: “Estrogens protect against breast cancer and can be used in selected cases for the treatment of breast cancer”.

For more information please read the abstract: Abstract COGI Estrogens and Breast Cancer

First patient enrolled in clinical study with the fetal estrogen estetrol (E4) in patients with advanced breast cancer (the ABCE4 study)

The first patient has been enrolled in the Phase I/II clinical trial assessing safety and efficacy of estetrol (E4) in postmenopausal women with advanced ER+ breast cancer. The study is a multi-center, open-label, dose-escalation study with a 3 + 3 cohort design to determine the recommended dose of E4 for the treatment of patients with advanced breast cancer. In total 9-18 patients will be enrolled at three centers in Germany.

The main objectives of this study are to evaluate the safety, the effects on estrogen deficiency symptoms and the preliminary anti-tumor activity of E4 in patients with advanced breast cancer.

Contribution of Pantarhei Bioscience to the Congress of the European Society of Gynecology (ESG), 18-21 October, 2017 in Barcelona by an invited lecture of Herjan Coelingh Bennink

Symposium on Sexuality / Women’s Sexual Dysfunction
Friday October 20, 2017

Chairpersons: Ali Kubba and Josep Perello

Programme:

Rossella E. Nappi:
Sexual symptoms at menopause: are they all women’s dysfunction?

Johannes Bitzer:
Sexual health care for cancer patients.

Rik HW van Lunsen:
The Amsterdam multifacettel approach of sexual pain disorders aiming at restoring sexual pleasure.

Herjan J.T. Coelingh Bennink:
Improvement of sexual function during pill use by normalising free testosterone levels.

For more information please read the abstract: Abstract ESG Barcelona Oct 2017

 

IMPRINT

Pantarhei Bioscience BV | Boulevard 17 | 3707 BK Zeist | The Netherlands
Phone: +31 (0)30 6 985 020 | Email: info@pantarheibio.com

DISCLAIMER

The information contained in this website is for general information purposes only. The information is provided by Pantarhei Bioscience and while we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.

SOCIAL MEDIA